Unknown

Dataset Information

0

Universal CARs, universal T cells, and universal CAR T cells.


ABSTRACT: Currently, the two approved T cell products with chimeric antigen receptors (CAR) are from autologous T cells. These CAR T cells approved for clinical use must be generated on a custom-made basis. This case-by-case autologous T cell production platform remains a significant limiting factor for large-scale clinical application due to the costly and lengthy production process. There is also an inherent risk of production failure. The individualized, custom-made autologous CAR T cell production process also posts constriction on the wide application on diverse tumor types. Therefore, universal allogeneic T cells are needed for the preparation of universal CAR T cells that can serve as the "off-the-shelf" ready-to-use therapeutic agents for large-scale clinical applications. Genome-editing technologies including ZFN (zinc finger nuclease), TALEN (transcription activator-like effector nuclease), and CRISPR-Cas9 are being used to generate the universal third-party T cells. In addition, split, universal, and programmable (SUPRA) CARs are being developed to enhance the flexibility and controllability of CAR T cells. The engineered universal T cells and universal CARs are paving the road for a totally new generation of CAR T cells capable of targeting multiple antigens and/ or being delivered to multiple recipients without re-editing of T cells. This may escalate to a new wave of revolution in cancer immunotherapy. This review summarized the latest advances on designs and development of universal CARs, universal T cells, and clinical application of universal CAR T cells.

SUBMITTER: Zhao J 

PROVIDER: S-EPMC6257951 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Universal CARs, universal T cells, and universal CAR T cells.

Zhao Juanjuan J   Lin Quande Q   Song Yongping Y   Liu Delong D  

Journal of hematology & oncology 20181127 1


Currently, the two approved T cell products with chimeric antigen receptors (CAR) are from autologous T cells. These CAR T cells approved for clinical use must be generated on a custom-made basis. This case-by-case autologous T cell production platform remains a significant limiting factor for large-scale clinical application due to the costly and lengthy production process. There is also an inherent risk of production failure. The individualized, custom-made autologous CAR T cell production pro  ...[more]

Similar Datasets

| S-EPMC4491658 | biostudies-literature
| S-EPMC6376657 | biostudies-literature
| S-EPMC8452787 | biostudies-literature
| S-EPMC8027274 | biostudies-literature
| S-EPMC8621371 | biostudies-literature
| S-EPMC5739565 | biostudies-literature
| S-EPMC7240059 | biostudies-literature
| S-EPMC10245878 | biostudies-literature
| S-EPMC9214433 | biostudies-literature
| S-EPMC5413401 | biostudies-literature